Fundraising Fox
4C Medical Technologies
Maple Grove, US · Founded 2015 · Delaware corporation · 2 known investors
Find your way into 4C Medical Technologies
Sign up to find every way you can get introduced to 4C Medical Technologies
- Your email: who you already know at 4C Medical Technologies, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the 4C Medical Technologies team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
4C Medical develops minimally invasive medical devices for structural heart disease, including mitral and tricuspid valve treatments. The company serves interventional cardiologists and patients requiring catheter-based cardiac interventions.
Founders & leadership
JF
James FlahertyExecutive
SK
Saravana KumarPresident, CEO & Board Member
Board
Investors · 2
Grant Park Ventureslisted by Grant Park VenturesLos Altos
How we know: Grant Park Ventures's portfolio page · Not right? Tell us
Anges QuébecreportedMontreal
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$145.5M disclosed across 7 rounds · 2016–2025
▶$71.6MraisedMar 2026 · 80 investors · Other TechnologyRule 506(b)
▶$71.6MraisedMar 2026 · 80 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey ChambersDirector
- Jonathan ChenDirector
- Rhonda RobbDirector
- Harley HandegardExecutive Officer
- Katherine KumarExecutive Officer
- Saravana KumarExecutive Officer, Director
- Buzz BensonDirector
- Offering amount
- $166.1M
- Amount sold
- $71.6M
- Sales commissions
- $9.3M
- Placement agents
- Piper Sandler & Co.
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.3MraisedNov 2021 · 53 investors · Other TechnologyRule 506(b)
▶$35.3MraisedNov 2021 · 53 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Saravana KumarExecutive Officer, Director
- Buzz BensonDirector
- Jeffrey W. ChambersDirector
- Rhonda RobbDirector
- Katherine KumarExecutive Officer
- Scott YoungstromExecutive Officer
- Jonathan ChenDirector
- Offering amount
- $60.6M
- Amount sold
- $35.3M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJun 2021 · 39 investors · Other TechnologyRule 506(b)
▶$10MraisedJun 2021 · 39 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Scott YoungstromExecutive Officer
- Saravana KumarExecutive Officer, Director
- Buzz BensonDirector
- Katherine KumarExecutive Officer
- Jonathan ChenDirector
- Jeffrey W. ChambersExecutive Officer, Director, Promoter
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.2MraisedOct 2019 · 45 investors · Other TechnologyRule 506(b)
▶$8.2MraisedOct 2019 · 45 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- William HoffmanDirector
- Katherine KumarExecutive Officer
- Saravana KumarExecutive Officer
- Robert J. ThatcherExecutive Officer, Director
- Jeffrey W. ChambersExecutive Officer, Director, Promoter
- Jonathan ChenDirector
- Buzz BensonDirector
- James E. FlahertyExecutive Officer
- Offering amount
- $20M
- Amount sold
- $8.2M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$17.3MraisedSep 2018 · 23 investors · Other TechnologyRule 506(b)
▶$17.3MraisedSep 2018 · 23 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- William HoffmanDirector
- Katherine KumarExecutive Officer
- James E. FlahertyExecutive Officer
- Saravana KumarExecutive Officer
- Jeffrey W. ChambersExecutive Officer, Director, Promoter
- Robert J. ThatcherExecutive Officer, Director
- Jonathan ChenDirector
- Offering amount
- $25M
- Amount sold
- $17.3M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.1MraisedMay 2018 · 29 investors · Other TechnologyRule 506(b)
▶$3.1MraisedMay 2018 · 29 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey W. ChambersExecutive Officer, Director, Promoter
- James E. FlahertyExecutive Officer
- Katherine KumarExecutive Officer
- Saravana KumarExecutive Officer
- William HoffmanDirector
- Robert J. ThatcherExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $3.1M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$60KraisedDec 2016 · 1 investors · Other TechnologyRule 506(b)
▶$60KraisedDec 2016 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Robert ThatcherExecutive Officer, Director
- James FlahertyExecutive Officer
- Jeffrey W. ChambersDirector, Promoter
- Offering amount
- $2M
- Amount sold
- $60K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Edwards LifesciencesEdwards Lifesciences develops innovative medical technologies for treating cardiovascular disease, focusing on structural heart interventions. The company serves patients and healthcare providers globally through partnerships with clinicians and healthcare stakeholders.
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
CardiovalveCardiovalve develops a transcatheter valve replacement system designed to fit both mitral and tricuspid anatomies via transfemoral delivery, avoiding open heart surgery. The device targets structural heart disease and is currently restricted to research use.
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
FoldaxFoldax develops heart valve replacement technology leveraging polymer expertise and biologic design. The company targets patients who require valve replacement, particularly young women with rheumatic disease in developing countries and aging patients in developed markets facing multiple surgeries.
Companies working in the same space as 4C Medical Technologies.
In the news
Frequently asked questions
- What does 4C Medical Technologies do?
- 4C Medical develops minimally invasive medical devices for structural heart disease, including mitral and tricuspid valve treatments. The company serves interventional cardiologists and patients requiring catheter-based cardiac interventions.
- Who are 4C Medical Technologies's investors?
- 4C Medical Technologies's investors include Grant Park Ventures, Anges Québec.
- How much funding has 4C Medical Technologies raised?
- 4C Medical Technologies has disclosed $145.5M raised across 7 rounds.
- Where is 4C Medical Technologies headquartered?
- 4C Medical Technologies is headquartered in Maple Grove, US.